☆ 4.8 Article

A chitosan-mediated inhalable nanovaccine against SARS-CoV-2

NANO RESEARCH (2022)

Related references

Note: Only part of the references are listed.

Review Immunology

Mucosal vaccines - fortifying the frontiers

Ed C. Lavelle et al.

Summary: Mucosal vaccines have the potential to prevent infections and protect against disease development by inducing adaptive immunity at mucosal sites. However, most current mucosal vaccines consist of live attenuated and inactivated whole-cell preparations, and there is a need for safe and effective mucosal adjuvants and innovative antigen discovery and delivery strategies to advance these vaccines. Advancements in understanding innate and adaptive mucosal immunity, including mucosal antigen-presenting cells and resident memory cells, provide valuable insights to inform mucosal adjuvant design for pathogens like SARS-CoV-2 and cancer.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis

Qiutong Jin et al.

Summary: This study developed an inhaled immunotherapeutic chitosan-antibody complex that effectively activates the immune system, promotes infiltration of different immune cells around tumor lesions, and prolongs the survival of mice.

ADVANCED MATERIALS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Virology

HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV

Aleksandra Milewska et al.

Summary: The compound HTCC has been found to have broad-spectrum antiviral activity, effectively blocking MERS-CoV and SARS-CoV-2 infections; the polymer acts by interacting with the S protein to prevent virus entry into host cells.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Allergy

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Carlo Cervia et al.

Summary: The study found that severe COVID-19 patients experienced a significant increase in SARS-CoV-2 antibody titers after symptom onset, especially with high IgA titers, while mild cases may exhibit transient production of SARS-CoV-2-specific antibodies. Interestingly, some healthcare workers with negative serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?

Nivya Sharma et al.

Summary: Chitosan, a deacetylated polycationic polysaccharide derived from chitin, possesses antimicrobial properties and can be used in various industrial and medical applications. Chitosan and its derivatives exhibit antiviral activities against a wide spectrum of viruses, including human, animal, and plant viruses. Research suggests the potential of chitosan as a molecule to combat the SARS-CoV-2 virus.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

Add to Collection

Article Engineering, Environmental

Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19

Bin Zheng et al.

Summary: The COVID-19 pandemic poses a serious threat to global public health, prompting the need for vaccine development. Research has shown that designing a bionic-virus nanovaccine can effectively stimulate mucosal immunity and protect the body from respiratory virus infection.

CHEMICAL ENGINEERING JOURNAL (2021)

Add to Collection

Article Immunology

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Mark M. Painter et al.

Summary: The study found that after SARS-CoV-2 mRNA vaccination, CD4(+) T cell responses in naïve individuals were fast, while CD8(+) T cell responses developed gradually. Th1 and Tfh cell responses after the first dose were correlated with post-boost CD8(+) T cells and neutralizing antibodies.

IMMUNITY (2021)

Add to Collection

Article Multidisciplinary Sciences

Inhalable nanocatchers for SARS-CoV-2 inhibition

Han Zhang et al.

Summary: Amid the global COVID-19 pandemic caused by SARS-CoV2, scientists have developed a novel approach to combat the virus, by designing hACE2-containing nanocatchers to protect cells from infection and potentially provide an alternative treatment option. This innovative method shows promising results in inhibiting SARS-CoV-2 infections, including mutated strains, and offers great potential for future clinical use in the ongoing epidemic.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Cell Biology

Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help

Jernej Pusnik et al.

Summary: Memory B cells specific to the spike protein of SARS-CoV-2 are generated in smaller numbers but with superior function in individuals recovering from mild COVID-19, dependent on IL-21(+)CD4(+) T cells. In contrast, severely ill COVID-19 patients generate fewer efficient memory B cells with dependence on CD40L(+)CD4(+) T cells. Activation and exhaustion of memory B cells during COVID-19 are linked to CD4(+) T cell functions, with CD4(+) T cells recognizing membrane proteins showing stronger association with spike-specific memory B cells.

CELL REPORTS (2021)

Add to Collection

Article Immunology

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

Tuksin Jearanaiwitayakul et al.

Summary: The study showed that loading the receptor-binding domain of SARS-CoV-2 spike glycoprotein into N,N,N-trimethyl chitosan nanoparticles and administering it intranasally to mice induced robust local mucosal immunity and systemic antibody responses. This alternative route of vaccination not only stimulated local mucosal responses, but also the systemic compartment of the immune system.

VACCINES (2021)

Add to Collection

Letter Immunology

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil

Carolina Kymie Vasques Nonaka et al.

Summary: The case of reinfection from distinct virus lineages in Brazil with the E484K mutation raises concerns about the duration of protective immune responses against SARS-CoV-2, especially with the variant associated with escape from neutralizing antibodies. This highlights potential challenges for virus control measures.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease

Jonathan Wang et al.

Summary: Nanoparticles synthesized from chitosan showed promising mucoadhesive and permeation capabilities in vitro, with improved controlled release and serum delivery over 24 hours. Loading metformin into chitosan nanoparticles resulted in lower cyst burden in a PKD murine model, demonstrating good tolerance and kidney health. This study presents a novel, oral nanoformulation for chronic diseases like PKD, building upon previous chitosan-based drug delivery approaches.

JOURNAL OF CONTROLLED RELEASE (2021)

Add to Collection

Article Cell Biology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Ahmed O. Hassan et al.

Summary: The study demonstrates the immunogenicity and protective efficacy of an intranasally administered vaccine in non-human primates, showing that it induces neutralizing antibodies and T cell responses, effectively limiting or preventing infection of SARS-CoV-2 in the respiratory tract.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Chemistry, Multidisciplinary

A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant

Jun-Jun Wu et al.

Summary: The novel STING agonist CDGSF modified with phosphorothioate and fluorine exhibited potent antitumor effects and enhanced immune responses when used as an adjuvant in the SARS-CoV-2 vaccine, showcasing potential therapeutic and preventive applications.

CHEMICAL COMMUNICATIONS (2021)

Add to Collection

Review Chemistry, Medicinal

Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy

Jun-Jun Wu et al.

MEDICINAL RESEARCH REVIEWS (2020)

Add to Collection

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Add to Collection

Article Microbiology

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Michael Letko et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Review Immunology

Manipulation of the Innate Immune Response by Varicella Zoster Virus

Chelsea Gerada et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Universal coronavirus vaccines: the time to start is now

Luca T. Giurgea et al.

NPJ VACCINES (2020)

Add to Collection

Article Pharmacology & Pharmacy

A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion

Dean Tatlow et al.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2020)

Add to Collection

Review Cell Biology

Transmission Routes Analysis of SARS-CoV-2: A Systematic Review and Case Report

Huanjie Li et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

Add to Collection

Review Chemistry, Multidisciplinary

Chemical Strategies to Boost Cancer Vaccines

Wen-Hao Li et al.

CHEMICAL REVIEWS (2020)

Add to Collection

Review Environmental Sciences

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

Thamina Acter et al.

SCIENCE OF THE TOTAL ENVIRONMENT (2020)

Add to Collection

Article Immunology

Intranasal Delivery of a Chitosan-Hydrogel Vaccine Generates Nasal Tissue Resident Memory CD8+ T Cells That Are Protective against Influenza Virus Infection

James G. Bedford et al.

VACCINES (2020)

Add to Collection

Article Multidisciplinary Sciences

An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases

Yang Liu et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Nanoscience & Nanotechnology

Designable Immune Therapeutical Vaccine System Based on DNA Supramolecular Hydrogels

Yu Shao et al.

ACS APPLIED MATERIALS & INTERFACES (2018)

Add to Collection

Article Chemistry, Multidisciplinary

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Jun-Jun Wu et al.

CHEMICAL COMMUNICATIONS (2018)

Add to Collection

Article Immunology

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons

Elizabeth. C. Carroll et al.

IMMUNITY (2016)

Add to Collection

Review Cell Biology

Tight junctions: from simple barriers to multifunctional molecular gates

Ceniz Zihni et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)

Add to Collection

Article Chemistry, Multidisciplinary

Synthetic Multivalent Glycopeptide-Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor Cells

Hui Cai et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)

Add to Collection

Article Chemistry, Multidisciplinary

Variation of the Glycosylation Pattern in MUC1 Glycopeptide BSA Vaccines and Its Influence on the Immune Response

Hui Cai et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)

Add to Collection

Article Chemistry, Multidisciplinary

a Totally Synthetic, Self-Assembling, Adjuvant-Free MUC1 Glycopeptide Vaccine for Cancer Therapy

Zhi-Hua Huang et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)

Add to Collection

Review Immunology

Recent progress in mucosal vaccine development: potential and limitations

Nils Lycke

NATURE REVIEWS IMMUNOLOGY (2012)

Add to Collection

Article Biotechnology & Applied Microbiology

Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing Efficacy

Sergey S. Seregin et al.

MOLECULAR THERAPY (2009)

Add to Collection

Article Pharmacology & Pharmacy

Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier

Zhi-Xiang Yuan et al.

JOURNAL OF DRUG TARGETING (2007)

Add to Collection

Article Biotechnology & Applied Microbiology

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

RH See et al.

JOURNAL OF GENERAL VIROLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.